BY MARKETWIRE
-
Eli Lilly launches USD 15bn share buyback
Previously in the 4th quarter, the United States firm finished its previous share buyback program of USD 5bn.
-
Genmab delivers promising data from cancer drug in two new clinical trials
Test results program that people with formerly without treatment scattered huge B-cell lymphoma attained a general reaction price of 100% and a total reaction price of 87%, to name…
-
ALK receives approval for dust mite allergy tablet for children: First launches are on the way
The initial launches of the tablet computer for kids adverse house allergen are anticipated to occur over the coming months.
-
CHMP recommends label update for Ozempic
This enables an upgrade of Novo Nordisk medication Ozempic’s tag to mirror its result on kidney condition.
-
DNB Markets starts covering Zealand Pharma – sees great potential in weight-loss candidate
Rune Majlund Dahl additionally indicates Swiss Roche as one of the most likely companion for Zealand Pharma around.
-
Zealand Pharma enrolls first patient in new study with “crown jewel”
Chief Executive Officer Adam Steensberg has actually formerly explained the firm’s long-acting amylin analog, petrelintide, as the “crown gem” of Zealand Pharma&#…
-
Eli Lilly to test its anti-obesity drug for addiction
The firm’s screening will certainly refer to additive actions pertaining to compounds such as pure nicotine and alcohol.
-
Bavarian Nordic plans buyback worth roughly USD 21m
Much better than anticipated outcomes and reduced expenses lead Bavarian Nordic to begin redeeming shares.
-
Eli Lilly launches USD 15bn share buyback
Earlier in the fourth quarter, the US company completed its previous share buyback program of USD 5bn.
-
Genmab presents positive data on leukemia candidate
The full feedback price, where cancer cells is no more noticeable, was 39%.
